Biomol Ther.  2019 Jul;27(4):381-385. 10.4062/biomolther.2018.232.

4′-O-β-D-Glucosyl-5-O-Methylvisamminol Attenuates Pro-Inflammatory Responses and Protects against Oxidative Damages

Affiliations
  • 1Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University, Goyang 10326, Republic of Korea. keum03@dongguk.edu

Abstract

We attempted to examine anti-inflammatory and anti-oxidant effects of 4"²-O-β-D-glucosyl-5-O-methylvisamminol (GOMV), the first epigenetic inhibitor of histone phosphorylation at Ser10. While GOMV did not affect the viability of murine macrophage RAW 264.7 cells, it significantly suppressed lipopolysaccharide (LPS)-induced generation of prostaglandin Eâ‚‚ (PGEâ‚‚) and nitric oxide (NO) through transcriptional inhibition of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS). GOMV also scavenged free radicals in vitro, increased NF-E2-related factor 2 (NRF2), and activated antioxidant response element (ARE), thereby resulting in the induction of phase II cytoprotective enzymes in human keratinocyte HaCaT cells. Finally, GOMV significantly protected HaCaT cells against 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced oxidative intracellular damages. Together, our results illustrate that GOMV possesses anti-inflammatory and anti-oxidant activity.

Keyword

4′-O-β-D-glucosyl-5-O-methylvisamminol (GOMV); Reactive oxygen species (ROS); NF-E2-related factor 2 (NRF2); Antioxidant response element (ARE)

MeSH Terms

Antioxidant Response Elements
Antioxidants
Cyclooxygenase 2
Epigenomics
Free Radicals
Histones
Humans
In Vitro Techniques
Keratinocytes
Macrophages
NF-E2-Related Factor 2
Nitric Oxide
Nitric Oxide Synthase Type II
Phosphorylation
RAW 264.7 Cells
Antioxidants
Cyclooxygenase 2
Free Radicals
Histones
NF-E2-Related Factor 2
Nitric Oxide
Nitric Oxide Synthase Type II
Full Text Links
  • BT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr